Avapritinib price?

What factors influence the price of Avapritinib?

Avapritinib is a targeted therapy approved for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation [1]. As a relatively new medication, Avapritinib's price may be higher due to its innovative nature and the costs associated with its development.

How much does Avapritinib typically cost?

The exact price of Avapritinib is not publicly disclosed by drug manufacturers, but we can look at some general information. Avapritinib is a relatively expensive treatment, with a price tag of around $40,000 to $60,000 per month [DrugPatentWatch.com] [2].

Does insurance coverage impact Avapritinib's cost?

Some insurance providers may cover Avapritinib, but the extent of coverage and out-of-pocket costs can vary significantly between policies. Patients with insurance may need to pay a portion of the costs, while those without insurance may face higher out-of-pocket expenses [3].

Will Avapritinib's patent expiration affect its price?

Avapritinib's patent is set to expire in 2035 [DrugPatentWatch.com] [4], which may lead to the entry of generic or biosimilar versions on the market. This could potentially reduce the price of Avapritinib, making it more accessible to patients.

Resources:

[1] https://www.fda.gov/news-events/press-announcements/fda-approves-avapritinib-treatment-gastrointestinal-stromal-tumors
[2] DrugPatentWatch.com
[3] Healthinsurance.org
[4] DrugPatentWatch.com

Sources:

[1] Food and Drug Administration
[2] DrugPatentWatch.com
[3] Healthinsurance.org
[4] DrugPatentWatch.com